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ABSTRACT 
68Ga-NODAGA-RGDyK(cyclic) and FDG PET/CT were per- formed in a 39-year-old man for the 
work-up of a moderately differentiated carcinoma of the gastro-esophageal junction within a 
clinical study protocol. Although FDG PET images showed intense, diffuse hypermetabolic 
lesion activity, NODAGA-RGDyK illustrated the neo-angiogenesis process with tracer uptake 
clearly localized in non-FDG-avid perilesional structures. Neo-angiogenesis is characterized by 
ανβ3 integrin expression at the lesion surface of newly formed vessels. This case supports 
evidence that angiogenesis imaging might therefore be a crucial step in early disease 
identification and localization, metastatization potential, and in monitoring the efficacy of 
antiangiogenic therapies. 
 
Figure 1 
A 39-year-old man with a history of progressive dysphagia underwent a positron emission 
tomography/computed tomography with 18F-fluorodeoxyglucose (FDG PET/CT) in the 
diagnostic work-up of a known moderately differentiated carcinoma of the gastro-esophageal 
junction. Images showed intense diffuse hypermetabolic lesion activity (black arrowheads; A, 
D). Several radiolabeled monomeric cyclic arginine-glycine-aspartic (RGD) peptides and 
analogs have been developed for monitoring and quantifying integrin ανβ3 (a molecular target 
involved in angiogenesis) expression noninvasively in tumors with PET.1–3 Then, to investigate 
the tumor-associated neo-angiogenesis within a clinical study protocol, it was secondly 
performed 
a PET/CT 58 minutes after intravenous injection of 215 MBq of 68Ga-NODAGA-RGDyK(cyclic), 
a new 68Ga-labeled radiopharmaceutical binding to ανβ3 integrin through its RGD motif.4,5 
Oral and written informed consent were obtained. Images clearly illustrated the neo-
angiogenesis process by a NODAGA-RDGyK uptake of non–FDG-avid perilesional structures 
(white arrowheads; B, E). Indeed, neo-angiogenesis is characterized by an integrin expression 
at the lesion surface of newly formed vessels that differs from that present on native vessels. 
The ανβ3 integrin is highly expressed on activated endothelial cells during angiogenesis, 
playing an essential role regulating tumor growth, local invasiveness, and metastatic potential. 
It plays an important role in many pathological processes, such as rheumatoid arthritis, 
psoriasis, cardiovascular diseases, tumor growth, and tumor metastasis.6 To the best of our 
knowledge, this is the first human clinical PET imaging using 68Ga-NODAGA-RGDyK PET in 
esophageal cancer. It supports evidence that angiogenesis imaging might therefore be a 
crucial step in early disease identification and localization, metastatization potential, and in 
monitoring the efficacy of antiangiogenic therapies. (A) FDG PET (maximum-intensity-
projection) MIP; (B) 68Ga-NODAGA-RGDyK(cyclic) PET MIP; (C) CT images in axial and coronal 
views; (D) FDG PET/CT fusion; (E) 68Ga-NODAGA-RGDyK PET/CT fusion. 
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